bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

Bluebird bio to be acquired by Carlyle Group & SK Capital, offering up to $9.84/share based on product performance. Former Mirati CEO David Meek set to lead bluebird post-acquisition, with deal ...

For a full version of this story, visit STAT. Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $ ...

Bluebird’s lead CAR-T cancer cell therapy idecabtagene vicleucel (ide-cel) was last year hit with an FDA refuse-to-file letter, which required additional data on chemistry, manufacturing and ...

From my observations in the market, I believe one of the most interesting prospects these days for investors to consider is Blue Bird Corporation (NASDAQ:BLBD). The school bus manufacturer is ...

As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises "substantial doubt" about its ability to continue as a going concern.

Bird flu is here to stay. The H5N1 avian influenza is proliferating among U.S. cows and there are now two strains circulating among mammals and birds. Though there are only 68 confirmed cases in ...

A new report suggests that more Americans may be walking around with bird flu − and not even know it. Researchers from the Centers for Disease Control and Prevention randomly tested 150 ...